Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tolerated dose level; progression free survival of 6.8 months, though data are still maturing There are more than 50% of mesothelioma patients who are on trial and continue to be followed SOUTH SAN FRANCISCO, Calif., June 04, 2016 -- Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that updated data from the ongoing Phase 1b trial of FP-1039/GSK3052230 in mesothelioma patients were reported today in a poster presentation at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.